{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-019512","form_type":"8-K","ticker":"ATNM","cik":"0001388320","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2022-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.439756+00:00","generated_at":"2026-06-26T07:37:56.709218+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Actinium licenses Iomab-B to Immedica for $35M upfront plus up to $417M milestones","bullets":["Upfront payment of $35 million from Immedica upon signing.","Eligible for aggregate regulatory/commercial milestones up to ~$417 million.","Royalties in mid-20% range on net sales in certain countries in licensed territory.","Immedica gets exclusive rights in EUMENA; Actinium retains U.S. and rest-of-world rights.","Actinium continues to handle clinical development and manufacturing of Iomab-B."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-019512","json":"https://secwatch.observer/filing/0001213900-22-019512.json","markdown":"https://secwatch.observer/filing/0001213900-22-019512.md","text":"https://secwatch.observer/filing/0001213900-22-019512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022019512/0001213900-22-019512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022019512/ea158381-8k_actinium.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T07:37:56.709218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}